Sema4 Holdings Corp. (SMFR)
Market Closed
23 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS) Primary $
79. 92
+12.92
+19.28%
$
246.37M Market Cap
- P/E Ratio
0% Div Yield
2,138,279 Volume
- Eps
$ 67
Previous Close Day Range
63.63 80.49
Year Range
24.91 117.75
Want to track SMFR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
SMFR closed Monday higher at $79.92, an increase of 19.28% from Friday's close, completing a monthly increase of 12.15% or $8.66. Over the past 12 months, SMFR stock gained 4.05%.
SMFR is not paying dividends to its shareholders.
The last earnings report, released on Nov 13, 2023, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
SMFR Chart
Loading, please wait...
Sema4 Holdings Corp. (SMFR) FAQ
What is the stock price today?
The current price is $79.92.
On which exchange is it traded?
Sema4 Holdings Corp. is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is SMFR.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0%.
What is its market cap?
As of today, the market cap is 246.37M.
Has Sema4 Holdings Corp. ever had a stock split?
No, there has never been a stock split.
Sema4 Holdings Corp. Profile
| Medical - Healthcare Information Services Industry | Healthcare Sector | Jason Ryan CEO | NASDAQ (NGS) Exchange | 81663L101 Cusip |
| US Country | 1,200 Employees | - Last Dividend | - Last Split | - IPO Date |
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.
Contact Information
Address: North Tower
Phone: 800 298 6470
Website: https://www.sema4.com
2025 © Marketlog. All Rights Reserved.
